KR20220112951A - Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof - Google Patents
Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof Download PDFInfo
- Publication number
- KR20220112951A KR20220112951A KR1020210016522A KR20210016522A KR20220112951A KR 20220112951 A KR20220112951 A KR 20220112951A KR 1020210016522 A KR1020210016522 A KR 1020210016522A KR 20210016522 A KR20210016522 A KR 20210016522A KR 20220112951 A KR20220112951 A KR 20220112951A
- Authority
- KR
- South Korea
- Prior art keywords
- fermented
- mugwort
- dementia
- injin mugwort
- present
- Prior art date
Links
- 230000003078 antioxidant effect Effects 0.000 title claims abstract description 18
- 241000092668 Artemisia capillaris Species 0.000 title claims abstract description 13
- 235000008658 Artemisia capillaris Nutrition 0.000 title claims abstract description 13
- 230000002205 anti-dementic effect Effects 0.000 title claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 12
- 238000000034 method Methods 0.000 claims abstract description 19
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 18
- 239000000203 mixture Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 235000013376 functional food Nutrition 0.000 claims abstract description 11
- 241000192130 Leuconostoc mesenteroides Species 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 10
- 240000006891 Artemisia vulgaris Species 0.000 claims description 58
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 57
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 239000012138 yeast extract Substances 0.000 claims description 13
- 229940041514 candida albicans extract Drugs 0.000 claims description 10
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 claims description 9
- 235000003097 Artemisia absinthium Nutrition 0.000 claims description 9
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 claims description 9
- 239000001138 artemisia absinthium Substances 0.000 claims description 9
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 7
- 235000008434 ginseng Nutrition 0.000 claims description 7
- 206010012289 Dementia Diseases 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000007201 aphasia Diseases 0.000 claims description 4
- 206010003062 Apraxia Diseases 0.000 claims description 2
- 206010012218 Delirium Diseases 0.000 claims description 2
- 201000004810 Vascular dementia Diseases 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 206010027175 memory impairment Diseases 0.000 claims description 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 2
- 244000131316 Panax pseudoginseng Species 0.000 claims 1
- 238000000855 fermentation Methods 0.000 abstract description 21
- 230000004151 fermentation Effects 0.000 abstract description 21
- 230000000116 mitigating effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 description 21
- 239000000523 sample Substances 0.000 description 17
- 230000002401 inhibitory effect Effects 0.000 description 16
- 210000004027 cell Anatomy 0.000 description 15
- 102100033639 Acetylcholinesterase Human genes 0.000 description 14
- 108010022752 Acetylcholinesterase Proteins 0.000 description 14
- 229940022698 acetylcholinesterase Drugs 0.000 description 14
- 241000238814 Orthoptera Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 12
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 11
- 102100032404 Cholinesterase Human genes 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- -1 various flavonoids Chemical class 0.000 description 7
- 241000208340 Araliaceae Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 235000013373 food additive Nutrition 0.000 description 4
- 239000002778 food additive Substances 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229960003980 galantamine Drugs 0.000 description 4
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 230000001603 reducing effect Effects 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000002292 Radical scavenging effect Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- KMVWNDHKTPHDMT-UHFFFAOYSA-N 2,4,6-tripyridin-2-yl-1,3,5-triazine Chemical compound N1=CC=CC=C1C1=NC(C=2N=CC=CC=2)=NC(C=2N=CC=CC=2)=N1 KMVWNDHKTPHDMT-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000010421 standard material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- SMBBQHHYSLHDHF-UHFFFAOYSA-M 2-acetyloxyethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)OCC[N+](C)(C)C SMBBQHHYSLHDHF-UHFFFAOYSA-M 0.000 description 1
- WEQAAFZDJROSBF-UHFFFAOYSA-M 2-butanoylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CCCC(=O)SCC[N+](C)(C)C WEQAAFZDJROSBF-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 235000015763 Artemisia ludoviciana Nutrition 0.000 description 1
- 244000267790 Artemisia ludoviciana Species 0.000 description 1
- 235000007823 Artemisia sp Nutrition 0.000 description 1
- 244000298939 Artemisia sp Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000002792 antioxidant assay Methods 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000001522 artemisia absinthium l. herb extract Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 102000013498 tau Proteins Human genes 0.000 description 1
- 108010026424 tau Proteins Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229940119569 wormwood extract Drugs 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Genetics & Genomics (AREA)
- Polymers & Plastics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
본 발명은 항치매 및 항산화 활성을 가지는 인진쑥(Artemisia capillaris) 발효물 및 이의 제조방법에 관한 것이다.The present invention relates to a fermented product of Artemisia capillaris having anti-dementia and antioxidant activity and a method for preparing the same.
치매(dementia)란 그 자체가 하나의 질환을 의미하는 것은 아니고, 여러가지 원인에 의한 뇌손상에 의해 기억력을 위시한 여러 인지기능의 장애가 생겨 예전 수준의 일상생활을 유지할 수 없는 상태를 의미한다. 정상적으로 성숙한 뇌가 후천적인 외상이나 질병 등 외인에 의하여 손상 또는 파괴되어 전반적으로 지능, 학습, 언어 등의 인지기능과 고등 정신기능이 떨어지는 복합적인 증상으로, 치매의 유형 중 알츠하이머병이 약 75% 차지한다.Dementia does not mean a disease in itself, but refers to a state in which various cognitive functions including memory are impaired due to brain damage caused by various causes, making it impossible to maintain the previous level of daily life. It is a complex symptom in which the normally mature brain is damaged or destroyed by external factors such as acquired trauma or disease, and overall cognitive functions such as intelligence, learning, language, and higher mental functions are deteriorated. do.
알츠하이머병의 원인으로는 신경전달물질인 콜린성 뉴런세포의 합성 감소와 콜린분해효소에 의한 분해 증가, 뇌 조직에 베타 아밀로이드와 타우 단백질의 축적, 산화적 스트레스 등이 알려져 있다.The causes of Alzheimer's disease include decreased synthesis of cholinergic neuronal cells, a neurotransmitter, increased degradation by cholinergic enzymes, accumulation of beta-amyloid and tau proteins in brain tissue, and oxidative stress.
현재 콜린분해효소의 억제제로, 갈란타민(galantamine), 도네페질(donepezil), 리바스티그민(rivastigmine), 메만틴(memantine) 등이 있으나, 식욕 저하, 소화불량, 설사, 구토 및 체중 감소 등의 부작용이 있어 이를 대체할 수 있는 천연 항치매 물질에 대한 관심이 증가하고 있다.Current inhibitors of cholinergic enzymes include galantamine, donepezil, rivastigmine, and memantine. There is a growing interest in natural anti-dementia substances that can replace them due to side effects.
쑥(Artemisia sp.)은 알칼로이드, 다양한 플라보노이드를 포함한 페놀화합물 등이 다량 함유하고 있어 항산화, 항암, 항염증, 항비만, 항균성 등 여러 기능성을 가지고 있어, 이를 원료로 한 기능성 식품 또는 의약품 관련 연구 개발이 꾸준히 이루어지고 있다. Artemisia sp. contains a large amount of alkaloids and phenolic compounds including various flavonoids, and has various functions such as antioxidant, anticancer, anti-inflammatory, anti-obesity, and antibacterial properties. This is being done consistently.
더불어, 장내 미생물과 그의 대사산물이 뇌와 관련이 있다는 연구결과가 보고되었으며, 불안, 우울증 등과 같은 기분 장애뿐만 아니라 최근에는 노화와 관련된 신경퇴행성 질환에서의 인지기능에 대한 연구들이 보고되고 있다. In addition, research results have been reported that gut microbes and their metabolites are related to the brain, and recently, studies on cognitive function in age-related neurodegenerative diseases as well as mood disorders such as anxiety and depression have been reported.
통계청 및 중앙치매센터에 따르면, 2020년 우리나라는 전체 인구의 65세 이상인 인구 비율이 15.7%로, 고령 사회이며 머지않아 2025년에는 20%를 초과하여 초고령 사회가 될 것으로 보고되었으며, 우리나라 노인 치매 유병률은 10.2%로, 65세 이상인 치매 환자 수는 2020년 약 84만 명으로 그 수는 앞으로 계속 늘어날 것으로 예측된 바, 부작용이 적고 안전한 천연 항치매 치료제가 더욱 절실히 요구되고 있는 실정이다.According to the National Statistical Office and the Central Dementia Center, in 2020, the proportion of the population aged 65 years or older is 15.7% of the total population in Korea, which is an aged society. The prevalence rate is 10.2%, and the number of dementia patients over the age of 65 is about 840,000 in 2020, and the number is expected to continue increasing in the future.
본 발명의 목적은 우수한 항치매 및 항산화 활성을 가진 천연물의 발효물의 제조 방법을 제공하는 데에 있다.An object of the present invention is to provide a method for producing a fermented product of a natural product having excellent anti-dementia and antioxidant activity.
본 발명의 다른 목적은 상기 제조방법에 따라 제조된 천연물의 발효물을 제공하는 데에 있다.Another object of the present invention is to provide a fermented product of a natural product prepared according to the above production method.
본 발명의 또 다른 목적은 상기 발효물을 유효성분으로 함유하는 인지기능장애 예방, 치료 또는 개선용 조성물을 제공하는 데에 있다.Another object of the present invention is to provide a composition for preventing, treating or improving cognitive dysfunction containing the fermented product as an active ingredient.
상기의 목적을 달성하기 위하여, 본 발명은 인진쑥(Artemisia capillaris)을 KCTC14459BP로 기탁된 류코노스톡 메센테로이드 MKJW (Leuconostoc mesenteroides MKJW) 균주로 접종하여 발효시키는 단계;를 포함하는 인진쑥 발효물 제조방법을 제공한다.In order to achieve the above object, the present invention provides a method for producing a fermented Artemisia capillaris comprising: inoculating and fermenting Artemisia capillaris with a Leuconostoc mesenteroides MKJW ( Leuconostoc mesenteroides MKJW) strain deposited as KCTC14459BP. do.
본 발명은 상기 제조방법에 따라 제조된 인진쑥 발효물을 제공한다.The present invention provides a fermented mugwort fermented product prepared according to the above method.
본 발명은 상기 인진쑥 발효물을 유효성분으로 함유하는 인지기능장애 예방 또는 치료용 약학 조성물을 제공한다.The present invention provides a pharmaceutical composition for preventing or treating cognitive dysfunction containing the fermented wormwood fermented product as an active ingredient.
또한, 본 발명은 상기 인진쑥 발효물을 유효성분으로 함유하는 인지기능장애 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving cognitive dysfunction containing the fermented ginseng mugwort as an active ingredient.
본 발명에 따른 인진쑥 발효물 제조방법에 따라 류코노스톡 메센테로이드 MKJW 균주를 이용함으로써, 항균 활성이 뛰어나 유산균 발효가 어려운 쑥을 다른 균주에 비해 효과적으로 발효시킬 수 있으며, 질소원인 쌍별 귀뚜라미 및 효모 추출물을 첨가함으로써 쑥 함량이 높은 경우에도 발효가 잘 이루어질 수 있다.By using the leukonostok mesenteroid MKJW strain according to the Injin mugwort fermented product manufacturing method according to the present invention, it is possible to effectively ferment mugwort, which is difficult to ferment lactic acid bacteria because of its excellent antibacterial activity, compared to other strains, and pairwise cricket and yeast extracts, which are nitrogen sources, can be used. By adding it, fermentation can be performed well even when the mugwort content is high.
상기 제조방법에 따라 제조된 인진쑥 발효물은 우수한 항치매 및 항산화 활성을 가지므로, 인지기능장애 예방, 치료 또는 개선을 위한 약학 조성물 및 건강기능식품 조성물로 활용할 수 있다. Since the fermented ginseng mugwort prepared according to the above preparation method has excellent anti-dementia and antioxidant activity, it can be used as a pharmaceutical composition and a health functional food composition for preventing, treating or improving cognitive dysfunction.
도 1은 본 발명의 일 실시예에 따라 제조된 쑥 발효물의 인진쑥 함량별 생균수 변화를 나타낸 그래프이다.
도 2는 본 발명에 따른 최적 조건에서 발효된 쑥 발효물의 콜린분해효소 저해활성을 나타낸 그래프이다.
도 3은 균주에 따른 쑥 발효물의 생균수 변화를 비교한 그래프이다.1 is a graph showing the change in the number of live cells according to the Injin mugwort content of the mugwort fermented product prepared according to an embodiment of the present invention.
2 is a graph showing the cholinerase inhibitory activity of fermented mugwort fermented under optimal conditions according to the present invention.
3 is a graph comparing the change in the number of viable cells of fermented mugwort according to the strain.
이하, 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명자는 항균 활성이 뛰어나 유산균 발효가 어려운 쑥이 류코노스톡 메센테로이드 MKJW 균주를 이용함으로써 발효가 잘 진행되며, 특히 질소원으로 쌍별 귀뚜라미 또는 효모 추출물을 일정량 첨가하였을 때, 우수한 항치매 활성 및 항산화 활성을 가짐을 확인함으로써, 본 발명을 완성하였다.The present inventors have found that wormwood, which has excellent antibacterial activity and is difficult to ferment lactic acid bacteria, is fermented well by using the leukonostok mesenteroid MKJW strain. By confirming that it has, the present invention was completed.
본 발명은 인진쑥(Artemisia capillaris)을 KCTC14459BP로 기탁된 류코노스톡 메센테로이드 MKJW (Leuconostoc mesenteroides MKJW) 균주로 접종하여 발효시키는 단계;를 포함하는 인진쑥 발효물 제조방법을 제공한다.The present invention provides a method for producing a fermented Artemisia capillaris comprising: inoculating and fermenting Artemisia capillaris with a Leuconostoc mesenteroides MKJW strain deposited as KCTC14459BP.
본 명세서에서, "인진쑥(Artemisia capillaris)"은 국화과 쑥속에 속하는 다년생 초본형 낙엽관목으로, 자생력이 뛰어나고 줄기가 목질화되어 한겨울에도 죽지않고 나무처럼 여러 해를 살아가서 '사철쑥'이라고도 한다. 전통적으로 식용 및 약용으로 사용되어 왔고, 주요 약리 작용으로는 간 기능 보호, 혈압 강하, 해열, 이뇨 작용 등이 보고되었다.In the present specification, " Artemisia capillaris " is a perennial herbaceous deciduous shrub belonging to the genus Asteraceae and mugwort. It has excellent self-reliance, and its stems are woody and do not die even in midwinter and live for many years like a tree. It has been traditionally used for food and medicine, and the main pharmacological actions include protection of liver function, lowering of blood pressure, antipyretic, and diuretic action.
상기 제조방법에 있어서, 상기 발효시키는 단계는 질소원으로 쌍별 귀뚜라미 및 효모 추출물에서 선택된 하나 이상을 첨가하여 류코노스톡 메센테로이드 MKJW 균주로 발효가 수행될 수 있다.In the manufacturing method, the fermentation step may be performed by adding one or more selected from pairwise cricket and yeast extracts as a nitrogen source to leukonostok mesenteroid MKJW strain.
본 발명의 일 비교예에 따르면, 류코노스톡 메센테로이드 MKSR에서는 인진쑥이 잘 발효되지 않은 바, 동일한 류코노스톡 속 균주라도 발효 활성이 다를 수 있으며, 특히, 본 발명에 따른 류코노스톡 메센테로이드 MKJW 균주를 사용함으로써 인진쑥 함량이 높은 경우에도 발효가 잘 진행될 수 있다.According to a comparative example of the present invention, since Injin mugwort is not fermented well in leukonostok mesenteroid MKSR, fermentation activity may be different even in the same leuconostock sp. By using the strain, fermentation can proceed well even when the content of Injin mugwort is high.
바람직하게는, 상기 인진쑥은 발효물 전체 100 중량부에 대하여, 3 내지 10 중량부 포함될 수 있고, 상기 쌍별 귀뚜라미 또는 효모 추출물은 상기 인진쑥 1 중량부에 대하여, 0.01 내지 1 중량부 포함될 수 있다.Preferably, the Injin mugwort may be included in 3 to 10 parts by weight based on 100 parts by weight of the total fermented product, and the pairwise cricket or yeast extract may be included in 0.01 to 1 part by weight based on 1 part by weight of the Injin mugwort.
보다 바람직하게는, 상기 인진쑥이 5 내지 7 중량부 포함되고, 질소원으로 상기 쌍별 귀뚜라미가 0.1 내지 0.2 중량부, 상기 효모 추출물이 1 내지 2 중량부 첨가될 때, 상기 발효가 잘 진행될 수 있으며, 이에 따라 상기 인진쑥 발효물은 우수한 항치매 또는 항산화 활성을 가질 수 있다.More preferably, when 5 to 7 parts by weight of the wormwood is included, 0.1 to 0.2 parts by weight of the pairwise crickets as a nitrogen source, and 1 to 2 parts by weight of the yeast extract are added, the fermentation can proceed well, Accordingly, the fermented Injin mugwort may have excellent anti-dementia or antioxidant activity.
본 발명의 일 실험예에 따르면, 인진쑥 6.747%, 쌍별 귀뚜라미 0.176%, 효모 추출물 1.274%로 포함될 때, 아세틸콜린에스터레이즈(acetylcholinesterase, AChE) 및 부티릴콜린에스터레이즈(butyrylcholinesterase, BuChE) 저해활성이 유의하게 높은 값을 나타내었고, 특히 AChE 저해활성은 양성 대조군인 갈란타민(galantamine)과 비슷한 활성을 나타냄을 확인할 수 있었다.According to an experimental example of the present invention, when it contains 6.747% of mugwort mugwort, 0.176% of paired crickets, and 1.274% of yeast extract, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activity is significant. In particular, it was confirmed that the inhibitory activity of AChE exhibited similar activity to that of the positive control, galantamine.
또한, 인진쑥 6.747%, 쌍별 귀뚜라미 0.176%, 효모 추출물 1.274%로 포함될 때, 우수한 항산화 활성을 가지고 총 폴리페놀 함량도 높게 나타남을 확인할 수 있었다.In addition, it was confirmed that when it contained 6.747% wormwood, 0.176% paired crickets, and 1.274% yeast extract, it had excellent antioxidant activity and a high total polyphenol content.
본 발명은 상기 인진쑥 발효물 제조방법에 따라 제조된 인진쑥 발효물을 제공한다.The present invention provides a fermented mugwort fermented product prepared according to the method for preparing fermented mugwort ginseng.
상기 인진쑥 발효물은 KCTC14459BP로 기탁된 류코노스톡 메센테로이드 MKJW (Leuconostoc mesenteroides MKJW) 균주로 발효된 것으로, 동일한 류코노스톡 속의 균주를 사용하더라도 발효가 잘 일어나지 않음을 비교예를 통해 확인한 바, 상기 MKJW 균주로 발효된 발효물이라는 점에서 특징을 가진다.The Injin mugwort fermented product was fermented with Leuconostoc mesenteroides MKJW ( Leuconostoc mesenteroides MKJW) strain deposited as KCTC14459BP. It is characterized in that it is a fermented product fermented with a strain.
상기 인진쑥 발효물은 우수한 항치매 또는 항산화 활성을 가질 수 있다.The fermented ginseng mugwort may have excellent anti-dementia or antioxidant activity.
또한, 본 발명은 상기의 인진쑥 발효물을 유효성분으로 함유하는 인지기능장애 예방 또는 치료용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for preventing or treating cognitive dysfunction containing the fermented ginseng mugwort as an active ingredient.
상기 인진쑥 발효물은 우수한 항치매 또는 항산화 활성을 가지므로, 인지기능장애의 예방 또는 치료를 위한 약학 조성물로 사용될 수 있다.Since the fermented wormwood extract has excellent anti-dementia or antioxidant activity, it can be used as a pharmaceutical composition for the prevention or treatment of cognitive dysfunction.
상기 인지기능장애는 치매, 알츠하이성 치매, 혈관성 치매, 학습장애, 건망증, 실인증, 실어증, 실행증, 섬망 및 경도인지장애로 이루어진 군에서 선택된 것일 수 있으나, 이에 제한되는 것은 아니다.The cognitive dysfunction may be selected from the group consisting of dementia, Alzheimer's dementia, vascular dementia, learning disability, forgetfulness, aphasia, aphasia, apraxia, delirium and mild cognitive impairment, but is not limited thereto.
본 발명에 따른 약학 조성물은 약학적 분야의 통상적인 방법에 따라 제조될 수 있다.The pharmaceutical composition according to the present invention may be prepared according to a conventional method in the pharmaceutical field.
상기 약학 조성물은 상기 제형에 따라 약학적으로 허용가능한 적절한 담체와 배합될 수 있고, 필요에 따라, 부형제, 희석제, 분산제, 유화제, 완충제, 안정제, 결합제, 붕해제, 용제 등을 더 포함하여 제조할 수 있다. 상기 "약학적으로 허용 가능한"이란, 상기 약학 조성물에 노출되는 세포나 인간에게 독성이 없는 것을 의미하고, 상기 적절한 담체 등은 본 발명에 따른 인진쑥 발효물의 활성 및 특성을 저해하지 않는 것으로, 투여 형태 및 제형에 따라 달리 선택될 수 있다.The pharmaceutical composition may be combined with a suitable pharmaceutically acceptable carrier according to the formulation, and if necessary, excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, etc. can The "pharmaceutically acceptable" means that it is not toxic to cells or humans exposed to the pharmaceutical composition, and the appropriate carrier does not inhibit the activity and properties of the fermented Injin mugwort according to the present invention, and the dosage form and may be selected differently depending on the formulation.
본 발명에 따른 약학 조성물은 어떠한 제형으로도 적용될 수 있고, 보다 상세하게는 통상의 방법에 따라 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 비경구형 제형로 제형화하여 사용될 수 있다.The pharmaceutical composition according to the present invention can be applied in any dosage form, and more specifically, it can be used by formulating oral dosage forms, external preparations, suppositories, and parenteral dosage forms of sterile injection solutions according to conventional methods.
상기 경구형 제형 중 고형 제형은 정제, 환제, 산제, 과립제, 캡슐제 등의 형태로, 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 솔비톨, 만니톨, 셀룰로오스, 젤라틴 등을 섞어 조제할 수 있고, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 포함될 수 있다. 또한, 캡술제형의 경우 상기 언급한 물질 외에도 지방유와 같은 액체 담체를 더 포함할 수 있다.Among the oral dosage forms, solid dosage forms are in the form of tablets, pills, powders, granules, capsules, etc., and at least one or more excipients, for example, starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc may be included. In addition, the capsule formulation may further include a liquid carrier such as fatty oil in addition to the above-mentioned substances.
상기 경구형 제형 중 액상 제형은 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Among the oral dosage forms, liquid formulations include suspensions, solutions, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients, for example, wetting agents, sweeteners, fragrances, preservatives, etc. may be included. have.
상기 비경구 제형은 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 이에 제한되지 않고, 당해 기술 분야에 알려진 적합한 제제를 모두 사용 가능하다.The parenteral formulation may include a sterile aqueous solution, a non-aqueous solution, a suspension, an emulsion, a freeze-dried formulation, and a suppository. Non-aqueous solvents and suspending agents include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate. As the base of the suppository, witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogelatin, and the like can be used. Without being limited thereto, any suitable agent known in the art may be used.
또한, 본 발명에 따른 약학 조성물은 치료 효능의 증진을 위해 칼슘이나 비타민 D3 등을 더 첨가할 수 있다. In addition, the pharmaceutical composition according to the present invention may further add calcium, vitamin D3, or the like to enhance therapeutic efficacy.
본 발명에 따른 약학 조성물은 약학적으로 유효한 양으로 투여될 수 있다. 상기 "약학적으로 유효한 양"이란, 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미한다.The pharmaceutical composition according to the present invention may be administered in a pharmaceutically effective amount. The "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment and not to cause side effects.
상기 약학 조성물의 유효 용량 수준은 사용 목적, 환자의 연령, 성별, 체중 및 건강 상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 달리 결정될 수 있다. 예를 들어, 일정하지는 않지만 일반적으로 0.001 내지 100mg/kg으로, 바람직하게는 0.01 내지 10mg/kg을 일일 1회 내지 수회 투여될 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The effective dose level of the pharmaceutical composition may be determined according to the purpose of use, the age, sex, weight and health status of the patient, the type of disease, severity, drug activity, sensitivity to drug, administration method, administration time, administration route and excretion rate, treatment It may be determined differently depending on factors including the duration, formulation, or concurrently used drugs, and other factors well known in the medical field. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg, may be administered once to several times a day. The above dosage does not limit the scope of the present invention in any way.
본 발명에 따른 약학 조성물은 인지기능장애가 발생할 수 있는 임의의 동물에 투여할 수 있고, 상기 동물은 예를 들어, 인간 및 영장류뿐만 아니라 소, 돼지, 말, 개 등의 가축 등을 포함할 수 있다.The pharmaceutical composition according to the present invention may be administered to any animal capable of cognitive dysfunction, and the animal may include, for example, not only humans and primates, but also livestock such as cattle, pigs, horses, and dogs. .
본 발명에 따른 약학 조성물은 제제 형태에 따른 적당한 투여 경로로 투여될 수 있고, 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 투여 방법은 특히 한정할 필요 없이, 예를 들면, 경구, 직장 또는 정맥, 근육, 피하, 기관지내 흡입, 자궁내 경막 또는 뇌혈관내(intracere-broventricular) 주사 등의 통상적인 방법으로 투여될 수 있다.The pharmaceutical composition according to the present invention may be administered by an appropriate administration route according to the form of the formulation, and may be administered through various routes, either oral or parenteral, as long as it can reach the target tissue. The administration method is not particularly limited, and for example, oral, rectal or intravenous, intramuscular, subcutaneous, endobronchial inhalation, intrauterine dural or intracerebroventricular injection, etc. can be administered in a conventional manner. .
본 발명에 따른 약학 조성물은 인지기능장애의 예방 또는 치료를 위하여 단독으로 사용될 수 있고, 수술 또는 다른 약물 치료 등과 병용하여 사용될 수 있다.The pharmaceutical composition according to the present invention may be used alone for the prevention or treatment of cognitive dysfunction, or may be used in combination with surgery or other drug treatment.
또한, 본 발명은 상기의 인진쑥 발효물을 유효성분으로 함유하는 인지기능장애 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for preventing or improving cognitive dysfunction containing the fermented ginseng mugwort as an active ingredient.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the above-mentioned parts.
본 발명에 따른 건강기능식품 조성물에 있어서, 상기 건강기능식품은 분말, 과립, 정제, 캡슐, 시럽 또는 음료 등으로 제조될 수 있고, 상기 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 통상적인 의미의 식품을 모두 포함할 수 있다. 예를 들어, 음료 및 각종 드링크, 과실 및 그의 가공식품(과일통조림, 잼 등), 어류, 육류 및 그 가공식품(햄, 베이컨 등), 빵류 및 면류, 쿠키 및 스낵류, 유제품(버터, 치즈 등) 등이 가능하며, 통상적인 의미에서의 기능성 식품을 모두 포함할 수 있다. 또한 동물을 위한 사료로 이용되는 식품도 포함할 수 있다.In the health functional food composition according to the present invention, the health functional food may be prepared in powder, granule, tablet, capsule, syrup or beverage, etc., and there is no limitation in the form that the health functional food can take, It can include any food with meaning. For example, beverages and various drinks, fruits and their processed foods (canned fruit, jam, etc.), fish, meat and their processed foods (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ), etc. are possible, and may include all functional foods in a conventional sense. It may also include food used as feed for animals.
본 발명에 따른 건강기능식품 조성물은 당업계에서 통상적으로 사용되는 식품학적으로 허용가능한 식품 첨가제 및 적절한 기타 보조 성분을 더 포함하여 제조될 수 있다. 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정할 수 있다. 상기 '식품첨가물공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다.The health functional food composition according to the present invention may be prepared by further including pharmaceutically acceptable food additives and other suitable auxiliary ingredients commonly used in the art. Unless otherwise specified, the suitability as a food additive can be determined according to the standards and standards for the relevant item in accordance with the general rules and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety. The items listed in the 'Food Additives Codex' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, high pigment, and guar gum; Mixed preparations, such as a sodium L-glutamate preparation, a noodle-added alkali agent, a preservative preparation, and a tar dye preparation, etc. are mentioned.
상기 기타 보조 성분은 예를 들어, 향미제, 천연 탄수화물, 감미제, 비타민, 전해질, 착색제, 펙트산, 알긴산, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산화제 등을 추가로 함유할 수 있다. 특히, 상기 천연 탄수화물로는 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜을 사용할 수 있으며, 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The other auxiliary ingredients include, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents, etc. may further contain. In particular, as the natural carbohydrate, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol can be used. , as the sweetener, natural sweeteners such as taumatine and stevia extract or synthetic sweeteners such as saccharin and aspartame may be used.
본 발명에 따른 건강기능식품 조성물은 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 인지기능장애의 예방 또는 개선을 위한 보조제로 섭취될 수 있다.The health functional food composition according to the present invention has the advantage that there are no side effects that may occur during long-term administration of the drug using food as a raw material, unlike general drugs, and has excellent portability, and is an adjuvant for the prevention or improvement of cognitive dysfunction can be consumed as
또한, 본 발명은 인진쑥 발효물을 유효성분으로 함유하는 아세틸콜린에스터레이즈(acetylcholinesterase, AChE) 또는 부티릴콜린에스터레이즈(butyrylcholinesterase, BuChE) 억제용 시약 조성물을 제공한다.In addition, the present invention provides a reagent composition for inhibiting acetylcholinesterase (AChE) or butyrylcholinesterase (BuChE) containing a fermented mugwort fermented product as an active ingredient.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted for the above-mentioned parts.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, in order to help the understanding of the present invention, examples will be described in detail. However, the following examples are merely illustrative of the content of the present invention, and the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those of ordinary skill in the art.
<실시예 1> 인진쑥 함량별 발효물 제조<Example 1> Preparation of fermented products according to Injin mugwort content
인진쑥 함량별로 발효 가능 여부를 확인하기 위해서 인진쑥(Artemisia capillaris, AC; 산림글로벌㈜, 용인시) 4%, 5%, 6%, 8%, 10%에 2.5% (w/v) 글루코오스 (덕산약품, 안산시)를 첨가하고 고압멸균기 (121℃, 20분)로 멸균한 후, 5%(v/v) 류코노스톡 메센테로이드 MKJW (Leuconostoc mesenteroides MKJW; KCTC 14459BP) (약 7~8 log CFU/ml)를 접종하였다. 진탕배양기 (130rpm, 30℃)에서 24시간 동안 발효하였으며, 발효 후 60℃에서 30분간 가열하여 균을 사멸시켰다. 각 샘플을 잘 흔들어서 채취하여 0.1% 펩톤수로 단계 희석한 후 MRS agar 배지에 도말하였다. 배양기 (30℃)에 24시간 동안 넣어 배양하고 생균수를 측정하였다.In order to check whether it is possible to ferment by content of Injin mugwort ( Artemisia capillaris , AC; Forest Global Co., Ltd., Yongin City) 4%, 5%, 6%, 8%, 10% and 2.5% (w/v) glucose (Duksan Pharmaceutical, Ansan) and sterilized in an autoclave (121°C, 20 minutes), 5% (v/v) leuconostoc mesenteroides MKJW ( Leuconostoc mesenteroides MKJW; KCTC 14459BP) (about 7-8 log CFU/ml) was inoculated. It was fermented for 24 hours in a shaker incubator (130rpm, 30℃), and after fermentation, it was heated at 60℃ for 30 minutes to kill the bacteria. Each sample was shaken well, and after serial dilution with 0.1% peptone water, it was smeared on MRS agar medium. It was put in an incubator (30° C.) for 24 hours and cultured, and the number of viable cells was measured.
<실시예 2> 질소원을 첨가한 인진쑥 발효물 제조<Example 2> Preparation of Injin Artemisia Fermented Product Addition of Nitrogen Source
인진쑥에 질소원으로 쌍별 귀뚜라미 (Cricket Farm, Korea) 및 효모 추출물 (Difco, USA)을 첨가하였을 때 발효 가능 여부를 확인하기 위하여, 3~7% 인진쑥, 0~2% 쌍별 귀뚜라미, 0~2% 효모 추출물을 함량을 달리하여 17가지 조건을 선정하였다. In order to check whether fermentation is possible when paired crickets (Cricket Farm, Korea) and yeast extract (Difco, USA) are added to Injinwormwood as nitrogen sources, 3~7% Injinwormwood, 0~2% pairwise crickets, 0~2% yeast By varying the extract content, 17 conditions were selected.
17가지 샘플에 공통적으로 2.5% (w/v) 글루코오스를 첨가하였고, 멸균 후 5% (v/v) MKJW (약 7~8 log CFU/ml)를 접종하여 30℃에서 12시간 배양하였다. 발효 후 60℃에서 30분간 가열하여 균을 사멸시키고, 각 샘플을 잘 흔들어 채취하여 0.1% 펩톤수로 단계 희석한 후 MRS agar 배지에 도말하였다. 배양기 (30℃)에 24시간 동안 넣어 배양하여 생균수를 측정하였고, 원심분리 (6,000rpm, 4℃, 20분)하여 상등액과 침전물을 분리하였으며 상등액으로 pH를 측정하였다. 2.5% (w/v) glucose was commonly added to 17 samples, and after sterilization, 5% (v/v) MKJW (about 7-8 log CFU/ml) was inoculated and cultured at 30° C. for 12 hours. After fermentation, the bacteria were killed by heating at 60° C. for 30 minutes, and each sample was shaken well, diluted stepwise with 0.1% peptone water, and then plated on MRS agar medium. The number of viable cells was measured by culturing in an incubator (30°C) for 24 hours, centrifugation (6,000rpm, 4°C, 20 minutes) to separate the supernatant from the precipitate, and the pH was measured with the supernatant.
<실험예 1> 인진쑥 함량별 발효물의 생균수 및 pH 분석<Experimental Example 1> Analysis of the number of viable cells and pH of fermented products by content of Injin mugwort
상기 실시예 1에 따라 제조된 인진쑥 함량별 발효물의 생균수 및 pH를 분석한 결과, 인진쑥 함량이 4% 또는 5%인 경우 발효 24시간 후 생균수가 각각 8.48log CFU/ml 또는 7.58log CFU/ml로 발효 전보다 증가한 반면, 인진쑥 함량이 6%, 8% 또는 10%인 경우에는 각각 4.48log CFU/ml, 4.79log CFU/ml 또는 4.95log CFU/ml로 감소하였다. 이를 통해, 인진쑥 함량이 6% 이상인 경우부터는 균이 제대로 생육할 수 없는 환경이며 발효가 잘 되지 않음을 확인할 수 있다.As a result of analyzing the number of viable cells and the pH of the fermented product according to the Injin mugwort content prepared according to Example 1, when the Injin mugwort content was 4% or 5%, the number of viable cells after 24 hours of fermentation was 8.48log CFU/ml or 7.58log CFU/ml, respectively. was increased compared to before fermentation, but decreased to 4.48log CFU/ml, 4.79log CFU/ml or 4.95log CFU/ml, respectively, when the mugwort content was 6%, 8%, or 10%. Through this, it can be confirmed that when the content of wormwood is 6% or more, it is an environment in which bacteria cannot grow properly and fermentation is not good.
<실험예 2> 질소원을 첨가한 인진쑥 발효물의 생균수 및 pH 분석<Experimental Example 2> Analysis of the number of viable cells and pH of fermented Injin mugwort with nitrogen source added
상기 실시예 2에 따라 제조된 17가지의 질소원 첨가 인진쑥 발효물 샘플의 생균수 및 pH를 분석한 결과, 하기 표 1에 나타난 바와 같이, 17가지의 조건에서 발효 후 생균수가 모두 증가하였으며 pH도 모두 감소하는 것으로 나타났다. 이는 모든 조건에서 발효가 잘된 것으로 판단할 수 있으며, 균 생육에 필요 인자인 질소원의 첨가가 인진쑥 함량이 6% 이상인 7%에서도 균이 잘 증식할 수 있게 함을 확인할 수 있다.As a result of analyzing the number and pH of 17 kinds of nitrogen source-added fermented mugwort samples prepared according to Example 2, as shown in Table 1 below, the number of viable cells increased after fermentation under 17 conditions, and the pH was also appeared to decrease. This can be judged to be a good fermentation under all conditions, and it can be confirmed that the addition of a nitrogen source, which is a necessary factor for bacterial growth, enables the bacteria to proliferate well even at 7%, which is more than 6% of the wormwood content.
<실험예 3> 콜린분해효소 저해활성 및 항산화 활성 확인<Experimental Example 3> Confirmation of cholinease inhibitory activity and antioxidant activity
1. 콜린분해효소 저해활성 분석1. Cholinease inhibitory activity analysis
아세틸콜린에스터레이즈(acetylcholinesterase, AChE)는 뇌의 주된 콜린가수분해 효소로 신경 전달 물질인 아세틸콜린을 분해함으로써 일련의 반응을 통해 신경세포의 손상을 초래하여 기억력 결핍을 유발한다. 따라서 AChE 저해활성은 아세틸콜린의 분해를 억제하여 신경세포의 손상을 억제해줌으로 치매 예방 효과가 있다. 알츠하이머형 치매(Alzheimer’ disease)의 주요한 특징 중의 하나인 AChE의 활성 증가와 마찬가지로 부티릴콜린에스터레이즈(butyrylcholinesterase, BuChE) 활성의 증가는 주요한 특징 중 하나이다.Acetylcholinesterase (AChE) is a major cholinergic enzyme in the brain that breaks down the neurotransmitter acetylcholine and causes damage to nerve cells through a series of reactions, leading to memory deficits. Therefore, AChE inhibitory activity inhibits the breakdown of acetylcholine, thereby inhibiting damage to nerve cells, thereby preventing dementia. An increase in butyrylcholinesterase (BuChE) activity is one of the main characteristics, similar to an increase in AChE activity, which is one of the main characteristics of Alzheimer's disease.
AChE 및 BuChE 저해활성은 Sharififar 등 (2012)의 방법을 변형하여 측정하였다. 효소 용액 (AChE or BuChE, 2 U/ml) 5μl과 5,5-디티오-비스-(2-니트로벤조익산)[5,5-dithio-bis-(2-nitrobenzoic acid), DTNB, 1mM] 40μl, 샘플 용액 125μl을 96 well에 순서대로 분주하고 25℃에서 5분간 전-배양(pre-incubation) 시켰다. 기질 (acetylcholine iodide or butyrylthiocholine iodide, 7.5mM) 7.5μl을 첨가하여 25℃에서 15분간 412nm에서 흡광도를 측정하였다. AChE and BuChE inhibitory activity was measured by modifying the method of Sharifar et al. (2012). 5 μl of enzyme solution (AChE or BuChE, 2 U/ml) and 5,5-dithio-bis-(2-nitrobenzoic acid) [5,5-dithio-bis-(2-nitrobenzoic acid), DTNB, 1 mM] 40 μl and 125 μl of the sample solution were dispensed sequentially into 96 wells and pre-incubated at 25° C. for 5 minutes. 7.5 μl of a substrate (acetylcholine iodide or butyrylthiocholine iodide, 7.5 mM) was added, and absorbance was measured at 412 nm at 25° C. for 15 minutes.
대조군(control)은 샘플 대신 인산 완충용액(phosphate buffer, 200mM, pH 7.7)을 첨가하였고, 갈란타민(galantamine)은 양성 대조군으로 사용하였다. 콜린에스터레이즈 저해활성은 하기 식 1과 같이 시간 경과에 따른 흡광도를 기울기로 나타내어 대조군의 기울기와 샘플의 기울기를 백분율로 표시하였다:As a control, a phosphate buffer (phosphate buffer, 200 mM, pH 7.7) was added instead of the sample, and galantamine was used as a positive control. Cholinesterase inhibitory activity was expressed as the slope of the absorbance over time as shown in Equation 1 below, and the slope of the control group and the slope of the sample were expressed as a percentage:
<식 1><Equation 1>
% AChE 및 BuChE 저해활성 = [1 - (S sample/S control)] × 100% AChE and BuChE inhibitory activity = [1 - ( S sample / S control )] × 100
S control: 대조군의 기울기 S control : the slope of the control group
S sample: 샘플의 기울기 S sample : the slope of the sample
2. 항산화 활성 분석2. Antioxidant activity assay
1) FRAP (Ferric reducing activity power)은 Cermeno 등 (2016)의 방법을 변형하여 측정하였다. 샘플 50μl에 FRAP 시약 (300mM acetate buffer : 10mM 2,4,6-tripyridyl- s-triazine (TPTZ) : 20mM FeCl3·6H2O = 10 : 1 : 1 (v/v/v)로 혼합하여 37℃에서 15분간 가온) 1ml을 가하고 37℃에서 30분간 가열한 후 590nm에서 흡광도를 측정하였다. 표준물질로 FeSO4를 사용하였으며, mM FeSO4로 나타내었다.1) Ferric reducing activity power (FRAP) was measured by modifying the method of Cermeno et al. (2016). FRAP reagent (300mM acetate buffer : 10mM 2,4,6-tripyridyl- s-triazine (TPTZ) : 20mM FeCl 3 6H 2 O = 10 : 1 : 1 (v/v/v) was mixed in 50 μl of sample 37 After heating at ℃ for 15 minutes) 1ml was added and heated at 37℃ for 30 minutes, and absorbance was measured at 590nm. FeSO 4 was used as a standard material, and was expressed as mM FeSO 4 .
2) 환원력(reducing power)은 Lin과 Yen (1999)의 방법을 변형하여 측정하였다. 샘플 250μl과 0.2M SPB (pH 6.6) 250μl, 1% 포타슘 페리시아나이드(potassium ferricyanide) 25μl을 첨가하여 50℃에서 20분간 반응 후 10% 트리클로로아세틱 에시드(trichloracetic acid) 250μl을 첨가하여 반응을 정지시켰다. 10,000rpm에서 5분간 원심분리한 후 상등액 500μl과 증류수 500μl, 0.1% ferric chloride 100μl을 혼합하여 700nm에서 흡광도를 측정하였다. 환원력은 흡광도 값으로 나타내었다.2) The reducing power was measured by modifying the method of Lin and Yen (1999). 250 μl of sample, 250 μl of 0.2M SPB (pH 6.6), and 25 μl of 1% potassium ferricyanide were added and reacted at 50° C. for 20 minutes. Then, 250 μl of 10% trichloroacetic acid was added to the reaction. stopped After centrifugation at 10,000 rpm for 5 minutes, 500 μl of the supernatant, 500 μl of distilled water, and 100 μl of 0.1% ferric chloride were mixed and absorbance was measured at 700 nm. The reducing power was expressed as the absorbance value.
3) DPPH 라디칼 소거능은 Park 등(2015)의 방법을 변형하여 측정하였다. 샘플 300μl과 0.2mM 2,2-Diphenyl-1-picrylhydrazyl (DPPH, Sigma Aldrich, StLouis, USA) 1.2ml를 혼합하여 암실에서 30분간 반응하고 517nm에서 흡광도 측정였다 (식 2). 대조군은 샘플 대신 메탄올을 첨가하였다.3) DPPH radical scavenging ability was measured by modifying the method of Park et al. (2015). 300 μl of sample and 1.2 ml of 0.2
<식 2><
DPPH 라디칼 소거 활성 (%) = [(Abs control - Abs sample)/Abs control] × 100DPPH radical scavenging activity (%) = [( Abs control - Abs sample )/ Abs control ] × 100
Abs control: 대조군의 흡광도 Abs control : Absorbance of control group
Abs sample: 샘플의 흡광도 Abs sample : absorbance of the sample
4) 총 폴리페놀 함량(total polyphenol content)은 Foline-ciocalteu 법으로 Anesini 등 (2008)의 방법을 변형하여 측정하였다. 샘플 0.2ml과 10배 희석한 Folin-ciocalteu 시약 1ml을 혼합하고 7.5% (w/v) Na2CO3 0.8ml을 첨가하였다. 실온에서 1시간 방치한 후 765nm에서 흡광도를 측정하였다. 표준물질로 갈산(gallic acid)을 사용하였으며 mg GAE/ml로 나타내었다.4) The total polyphenol content was measured by modifying the method of Anesini et al. (2008) using the Foline-ciocalteu method. 0.2 ml of the sample and 1 ml of Folin-ciocalteu reagent diluted 10 times were mixed, and 0.8 ml of 7.5% (w/v) Na 2 CO 3 was added. After standing at room temperature for 1 hour, absorbance was measured at 765 nm. Gallic acid was used as a standard material and expressed as mg GAE/ml.
하기 표 2는 실시예 2에 따라 제조된 17가지 조건의 발효물의 콜린분해효소 저해활성 및 항산화 활성 측정 결과이다.Table 2 below shows the measurement results of cholinease inhibitory activity and antioxidant activity of the fermented product under 17 conditions prepared according to Example 2.
상기 표 2를 참조하면, AChE 및 BuChE 저해활성은 쑥 함량과 효모 추출물 함량이 증가하고 쌍별 귀뚜라미 함량이 감소할 경우 증가하는 것으로 나타났다. 가장 높은 활성을 갖는 조건은 인진쑥 7%, 효모 추출물 1% (8번 샘플)로 각각 91.9%, 82.4%의 활성을 나타냈다. Referring to Table 2, the inhibitory activity of AChE and BuChE was found to increase when the mugwort content and yeast extract content increased and the pairwise cricket content decreased. The conditions with the highest activity were 7% of Artemisia Artemisia and 1% of yeast extract (sample No. 8), which showed 91.9% and 82.4% of activity, respectively.
FRAP, 환원력(reducing power), DPPH 라디칼 소거 활성 등의 항산화 활성은 인진쑥 7%, 쌍별 귀뚜라미 1%, 효모 추출물 2% (14번 샘플)일 때 가장 높은 것으로 나타났다.Antioxidant activities such as FRAP, reducing power, and DPPH radical scavenging activity were highest when 7% of wormwood, 1% of paired crickets, and 2% of yeast extract (sample 14).
<실험예 4> 최적 조건에서의 활성 분석<Experimental Example 4> Activity analysis under optimal conditions
상기 실험예 들을 통해 인진쑥 6.747%, 쌍별 귀뚜라미 0.176%, 효모 추출물 1.274%의 최적 조건을 선정하고, 이 때의 조건으로 12시간 발효한 경우의 활성을 분석하였다.Through the above experimental examples, optimal conditions of 6.747% of mugwort wormwood, 0.176% of paired crickets, and 1.274% of yeast extract were selected, and the activity of 12 hours of fermentation was analyzed under these conditions.
하기 표 3은 상기 최적 조건에서의 쑥 발효물의 생균수 및 pH 측정 결과이다.Table 3 below shows the results of measuring the number of viable cells and pH of the mugwort fermented product under the optimal conditions.
상기 표 3을 참조하면, 발효 후 생균수는 6.82log CFU/ml에서 8.14log CFU/ml로 증가하였고 pH는 5.16에서 4.93으로 감소한 것으로 나타났다. 이는 발효가 잘 진행되었다고 할 수 있다.Referring to Table 3, after fermentation, the number of viable cells increased from 6.82log CFU/ml to 8.14log CFU/ml, and the pH decreased from 5.16 to 4.93. It can be said that the fermentation proceeded well.
하기 표 4는 상기 최적 조건에서의 쑥 발효물의 콜린분해효소 저해활성 측정 결과이다.Table 4 below shows the measurement results of the cholinerase inhibitory activity of the mugwort fermented product under the optimal conditions.
상기 표 4 및 도 2를 참조하면, AChE 저해 활성은 91.1%이며 이는 양성 대조군인 갈란타민(galantamine)과 비슷한 활성임을 확인할 수 있으며, BuChE 저해 활성은 74.0%로 나타났다. Referring to Table 4 and FIG. 2, the AChE inhibitory activity was 91.1%, which was confirmed to be similar to that of the positive control, galantamine, and the BuChE inhibitory activity was 74.0%.
하기 표 5는 상기 최적 조건에서의 쑥 발효물의 항산화 활성 및 총 폴리페놀 함량 측정 결과로, 높은 항산화 활성 및 총 폴리페놀 함량을 나타내었다.Table 5 below shows the high antioxidant activity and total polyphenol content as a result of measuring the antioxidant activity and total polyphenol content of the mugwort fermented product under the optimal conditions.
<비교예 1> 류코노스톡 메센테로이드 균주에 따른 쑥 발효물 분석<Comparative Example 1> Analysis of fermented mugwort according to Leukonostok mesenteroid strain
5% 인진쑥과 2% 쌍별 귀뚜라미를 혼합한 혼합물에 2 종류의 프로바이오틱 균주, 류코노스톡 메센테로이드 MKSR (MKSR)와 류코노스톡 메센테로이드 MKJW (MKJW)를 종균(5%)으로 하여 24시간 발효하여 생균수를 분석한 결과, 도 3에 나타난 바와 같이, MKSR은 발효 후 생균수가 증가하지 않은 반면, MKJW는 9.21log CFU/ml로 발효 후 생균수가 유의하게 증가하였음을 확인할 수 있다.2 types of probiotic strains, Leukonostok Mesenteroid MKSR (MKSR) and Leukonostok Mesenteroid MKJW (MKJW) in a mixture of 5% wormwood and 2% pairwise crickets as a starter (5%) for 24 hours As a result of analyzing the number of viable cells by fermentation, as shown in FIG. 3 , it can be confirmed that the number of viable cells after fermentation was significantly increased in MKJW to 9.21log CFU/ml, whereas in MKSR, the number of viable cells did not increase after fermentation.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.As described above in detail a specific part of the present invention, for those of ordinary skill in the art, it is clear that this specific description is only a preferred embodiment, and the scope of the present invention is not limited thereby. do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (10)
상기 발효시키는 단계는,
질소원으로 쌍별 귀뚜라미 및 효모 추출물에서 선택된 하나 이상을 첨가하는 것을 특징으로 하는 인진쑥 발효물 제조방법.The method of claim 1,
The fermenting step is
A method for producing fermented Injin mugwort, characterized in that by adding at least one selected from pairwise cricket and yeast extracts as a nitrogen source.
상기 인진쑥은,
발효물 전체 100 중량부에 대하여, 3 내지 10 중량부 포함되는 것을 특징으로 하는 인진쑥 발효물 제조방법.The method of claim 1,
The Injin mugwort,
Based on 100 parts by weight of the total fermented product, 3 to 10 parts by weight of Injin mugwort fermented product manufacturing method, characterized in that it is included.
상기 쌍별 귀뚜라미 또는 효모 추출물은,
상기 인진쑥 1 중량부에 대하여, 0.01 내지 1 중량부 포함되는 것을 특징으로 하는 인진쑥 발효물 제조방법.3. The method of claim 2,
The pairwise cricket or yeast extract,
Based on 1 part by weight of the Injin mugwort, 0.01 to 1 part by weight is included.
상기 인진쑥 발효물은,
항치매 또는 항산화 활성을 갖는 것을 특징으로 하는 인진쑥 발효물 제조방법.The method of claim 1,
The fermented injin mugwort,
A method for producing fermented Injin mugwort, characterized in that it has anti-dementia or antioxidant activity.
상기 인진쑥 발효물은,
항치매 또는 항산화 활성을 갖는 것을 특징으로 하는 인진쑥 발효물.7. The method of claim 6,
The fermented injin mugwort,
Injin mugwort fermented product, characterized in that it has anti-dementia or antioxidant activity.
상기 인지기능장애는,
치매, 알츠하이성 치매, 혈관성 치매, 학습장애, 건망증, 실인증, 실어증, 실행증, 섬망 및 경도인지장애로 이루어진 군에서 선택된 것을 특징으로 하는 인지기능장애 예방 또는 치료용 약학 조성물.9. The method of claim 8,
The cognitive dysfunction is
A pharmaceutical composition for preventing or treating cognitive dysfunction, characterized in that it is selected from the group consisting of dementia, Alzheimer's dementia, vascular dementia, learning disability, forgetfulness, aphasia, aphasia, apraxia, delirium and mild cognitive impairment.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210016522A KR102463087B1 (en) | 2021-02-05 | 2021-02-05 | Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210016522A KR102463087B1 (en) | 2021-02-05 | 2021-02-05 | Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220112951A true KR20220112951A (en) | 2022-08-12 |
| KR102463087B1 KR102463087B1 (en) | 2022-11-03 |
Family
ID=82803947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210016522A KR102463087B1 (en) | 2021-02-05 | 2021-02-05 | Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102463087B1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040094512A (en) * | 2003-05-02 | 2004-11-10 | 주식회사 벤스랩 | Functional Food Composition having Anti-oxidative, Anti-arthritic and Anti-dementia Activity |
| KR20090098254A (en) | 2008-03-13 | 2009-09-17 | 김진섭 | Method for producing artemisia extract by fermentation |
| KR20110027415A (en) * | 2009-09-10 | 2011-03-16 | 주식회사 파인엠 | Microoranism capable of growing with artemisia sp. as carbon source and use thereof |
| KR20110058287A (en) * | 2009-11-26 | 2011-06-01 | (주)아모레퍼시픽 | Composition for promotion of peroxisome proliferator activated receptor delta |
| KR20130001779A (en) * | 2011-06-28 | 2013-01-07 | 주영철 | Composition prepared by fermenting extract from artemisia showing antioxidant activity and osteoblast proliferation activity and method for manufacturing the same |
| KR20140102888A (en) * | 2013-02-15 | 2014-08-25 | 한동대학교 산학협력단 | Culture media for lactic acid bacteria and culture and storage method of them in industrial scale |
-
2021
- 2021-02-05 KR KR1020210016522A patent/KR102463087B1/en active IP Right Grant
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040094512A (en) * | 2003-05-02 | 2004-11-10 | 주식회사 벤스랩 | Functional Food Composition having Anti-oxidative, Anti-arthritic and Anti-dementia Activity |
| KR20090098254A (en) | 2008-03-13 | 2009-09-17 | 김진섭 | Method for producing artemisia extract by fermentation |
| KR20110027415A (en) * | 2009-09-10 | 2011-03-16 | 주식회사 파인엠 | Microoranism capable of growing with artemisia sp. as carbon source and use thereof |
| KR20110058287A (en) * | 2009-11-26 | 2011-06-01 | (주)아모레퍼시픽 | Composition for promotion of peroxisome proliferator activated receptor delta |
| KR20130001779A (en) * | 2011-06-28 | 2013-01-07 | 주영철 | Composition prepared by fermenting extract from artemisia showing antioxidant activity and osteoblast proliferation activity and method for manufacturing the same |
| KR20140102888A (en) * | 2013-02-15 | 2014-08-25 | 한동대학교 산학협력단 | Culture media for lactic acid bacteria and culture and storage method of them in industrial scale |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102463087B1 (en) | 2022-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101807328B1 (en) | Dna damage repair promoter for oral application, and elastase activity inhibitor for oral application | |
| US20220160798A1 (en) | Method for producing spirulina extract, and spirulina extract-containing pharmaceutical composition and health functional food for improving cognitive ability | |
| KR102216651B1 (en) | composition for preventing neurological diseases and improving memory containing a fermented soybeans | |
| KR101720051B1 (en) | Pharmaceutical composition comprising fermented Aralia cordata Thunb for preventing or treating arthritis | |
| AU2016230139A1 (en) | Fermented tea product | |
| US11110145B2 (en) | Composition for protecting cell from oxidative stress comprising green tea extract which has modified amounts of ingredients | |
| JP4119656B2 (en) | Antioxidant | |
| KR102302933B1 (en) | Preparation of fermented garlic mixture and manufacturing method of composition effective for cardiovascular disease | |
| US20080275109A1 (en) | Neutralizing agent for vacuolating toxin | |
| KR102230517B1 (en) | Lactobacillus salivarius having anticariogenic activities and composition comprising the same | |
| KR102463087B1 (en) | Fermented artemisia capillaris having anti-dementia and anti-oxidative activity, and manufacturing method thereof | |
| US11607433B2 (en) | Composition for preventing, improving, or treating autism spectrum disorders including Agathobaculum sp. strain as active ingredient | |
| JP2013249260A (en) | Senescence retardant | |
| KR101302652B1 (en) | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS COMPRISING α-GLUCOSIDASE INHIBITOR AND BREWER'S DRIED YEAST | |
| JP2005206495A (en) | Health food for preventing cancer and medicinal composition | |
| KR20180075763A (en) | Composition comprising the ethanol extract of Portulacea oleracea for preventing and treating of Alcoholic liver damage | |
| KR102210092B1 (en) | Lactobacillus reuteri MG505 having anticariogenic activities and composition comprising the same | |
| KR101584513B1 (en) | A fermented boehmeria nivea for protecting brain neuroral cells and a fermented tea using the fermented boehmeria nivea | |
| KR20150037774A (en) | Preparation of clove having enhanced antioxidative effect | |
| JP2005206493A (en) | Anti-helicobacter pylori agent | |
| JP6381284B2 (en) | Composition for prevention and / or treatment of memory impairment | |
| EP4289438A1 (en) | Composition for preventing, alleviating or treating sleep disorders, containing, as active ingredient, gut microbiota or extracellular vesicles derived therefrom | |
| KR102618432B1 (en) | Paracoccus aminovorans bm109 strain and use thereof | |
| KR20180129579A (en) | Onion Coat composition Using An Enzyme With Stevia Extract And Method thereof | |
| RU2793287C2 (en) | Kimchi for the prevention or treatment of helicobacterpylori-related diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E90F | Notification of reason for final refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |